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Stool carriage of drug-resistant Escherichia coli in
home-living residents of a rural community was examined.
Carriage of nalidixic acid–resistant E. coli was associated
with recent use of antimicrobial agents in the household.
Household clustering of drug-resistant E. coli was
observed. Most carriers of drug-resistant E. coli lacked con-
ventional risk factors.
A
cquisition of drug-resistant Escherichia coli may be
influenced by food, exposure to flora of contacts, and
use of antimicrobial agents (1–3). Few community studies
have explored the contribution of these mechanisms to dis-
semination of drug-resistant E. coli in healthy persons
(4–6). We examined epidemiologic factors associated with
colonization by drug-resistant E. coli in home-living vol-
unteers who were not recruited through healthcare settings
(7,8). Resistance to trimethoprim/sulfamethoxazole
(TMP/SMZ), nalidixic acid (NA), and extended-spectrum
cephalosporins (ESCs) was examined (9,10).
The Study
From March to May 2002, a convenience sample of
household volunteers was recruited from 1 rural communi-
ty in Idaho. Consenting adults and parents of children com-
pleted an exposure questionnaire. The questionnaire
assessed dietary history and livestock contact during the
previous month, and other exposures, including antimicro-
bial drug use and travel outside the United States during the
past 6 months. The study was reviewed and approved by the
Western Institutional Review Board (Olympia, WA, USA).
Information on antimicrobial drug prescriptions filled
by community pharmacies in the preceding year was
obtained (beginning March 2001). Pharmacy-documented
antimicrobial drug prescriptions were compared with self-
reported use. The definition of antimicrobial drug use was
either pharmacy documentation of an antimicrobial drug
prescription or self-reported use of a named antimicrobial
agent obtained from a plausible nonpharmacy (e.g., free
sample from a doctor’s office) or out-of-area source, with
dates of use. Recent antimicrobial drug use was defined as
use <30 days before collection of stool swabs.
Study participants were instructed to use a CultureSwab
(Becton Dickinson, Franklin Lakes, NJ, USA) to collect
fecal material. All samples were refrigerated and transport-
ed to the Idaho State Bureau of Laboratories (state labora-
tory) in Boise, Idaho. At the state laboratory, samples were
streaked across 3 MacConkey agar plates, each containing
1 screening antimicrobial agent (16 mg/L TMP/SMZ, 16
mg/L NA, or 2 mg/L cefotaxime). One phenotypically dis-
tinct colony type per plate was further analyzed. 
Putative E. coli colonies were confirmed by using the
Microscan system (Dade Behring Inc., Deerfield, IL,
USA). Susceptibility was assessed by MIC using broth
microdilution (Microscan) for cefpodoxime, ceftazidime,
ceftriaxone, and TMP/SMZ and the Etest (AB-BIODISK,
Solna, Sweden) for NA. Manufacturer-specified proce-
dures and reference strains were used, along with Clinical
and Laboratory Standards (CSLI) (formerly National
Committee for Clinical Laboratory Standards [NCCLS])
guidelines. The CSLI/NCCLS criteria were used to classi-
fy isolates as resistant to TMP/SMZ, NA, or ESC.
Resistance to ESC was defined as resistance to ceftriaxone
(MIC >64 µg/mL), ceftazidime (MIC >32 µg/mL), or cef-
podoxime (MIC >8 µg/mL) (11). Asample was resistant if
at least 1 E. coli isolate from that sample exhibited the cor-
responding resistance phenotype. 
The primary endpoints were intestinal carriage of E.
coli resistant to the 3 targeted antimicrobial drug classes.
Carriage of NA-resistant and TMP/SMZ-resistant E. coli
were examined separately by comparing carriers and non-
carriers of NA-resistant and TMP/SMZ-resistant E. coli.
Regression models were constructed in which study partic-
ipants were divided into 3 mutually exclusive groups: car-
riers of NA-resistant E. coli (either TMP/SMZ resistant or
susceptible), carriers of TMP/SMZ-resistant/NA-suscepti-
ble E. coli, and persons who did not carry either resistance
(reference group). Crude and adjusted odds ratios were
estimated by using generalized estimating equations to
account for household-level clustering. Statistical signifi-
cance was defined as a p value <0.05. Analyses were per-
formed with Stata version 8.0 (Stata Corporation, College
Station, TX, USA).
Stool swabs were received from 517 study participants
representing 167 households (Table 1). The prevalence of
intestinal carriage of E. coli resistant to NA was 3%, to
TMP/SMZ 11%, and to ESCs 1%. All 6 ESC-resistant iso-
lates were found so based on their resistance to cefpo-
doxime. The ceftazidime MIC was in the susceptible range
for 5 of these isolates (<4 µg/mL for 2 and 8 µg/mL for 3)
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Use of antimicrobial agents was associated with car-
riage of NA-resistant but not TMP/SMZ-resistant E. coli;
6 (16%) of 37 study participants who used antimicrobial
agents within 30 days of culture carried NA-resistant E.
coli, compared with 10 (2%) of 480 participants who did
not use antimicrobial agents. However, significance was
lost after accounting for household clustering (p = 0.13).
Carriage of TMP/SMX-resistant E. coli was similar in per-
sons with and without recent use of antimicrobial agents;
5 (14%) of 37 study participants with recent use carried
TMP/SMZ-resistant E. coli compared with 50 (10%) of
480 persons without recent use (p = 0.84). 
A similar pattern was seen for recent use of antimicro-
bial agents in the household. Overall, 92 (18%) persons
resided in a household in which at least 1 member recent-
ly used antimicrobial agents. Of these, 11 (12%) of 92 car-
ried NA-resistant E. coli, compared with 5 (1%) of 425 in
households without recent use. In contrast, the prevalence
of carriage of TMP/SMX-resistant E. coli was similar in
persons with and without recent household use of antimi-
crobial agents. When we accounted for household cluster-
ing, recent use of antimicrobial agents in the household
was associated with 9.2-fold increased odds for carriage of
NA-resistant E. coli (p<0.001). Additionally, the presence
of another household member with NA-resistant E. coli
was associated with 8.8-fold increased odds for NA-resist-
ant E. coli carriage (p<0.001), and the presence of another
household member with TMP/SMZ-resistant E. coli was
associated with 2.7-fold increased odds for TMP/SMZ-
resistant E. coli carriage (p<0.001). Carriage of NA-resist-
ant or TMP/SMZ-resistant E. coli was not associated with
age, sex, livestock exposure, dietary history, contact with
the healthcare system, or travel outside the United States
(Table 2). Approximately 94% of persons in the study ate
chicken or ground beef in the previous month (Table 1); 14
of 17 persons who did not eat beef or chicken in the previ-
ous month were children <5 years of age. 
The 6 study participants who carried ESC-resistant E.
coli belonged to 6 separate households. None had used
antimicrobial agents within 30 days of culture and only 1
had household use of antimicrobial agents within 30 days.
No other epidemiologic or demographic factors distin-
guished this group. The small number of persons with car-
riage of ESC-resistant E. coli precluded further statistical
analysis of this endpoint. 
Of the 517 participants, 34% self reported use of an
antimicrobial agent during the previous 6 months (Table 3).
Of these, 67% had pharmacy documentation of at least 1
antimicrobial agent prescription. However, 22% of the 339
persons who reported not using antimicrobial agents had
pharmacy documentation of at least 1 prescription. Of the
178 persons who reported use of >1 antimicrobial agent,
108 (61%) provided the name of the agent. However, the
specific drug named matched the drug listed in the phar-
macy records for only 29% of the persons. Thirteen per-
sons reported receiving an antimicrobial agent from a
nonpharmacy source. Six of the 13 purchased antimicro-
bial agents in Mexico, 4 received a drug sample from their
healthcare provider, and 1 person each received the antimi-
crobial agent from a dairy, another family member, or a
leftover prescription.
Conclusions
Carriage of E. coli resistant to TMP/SMZ was more
common than carriage of E. coli resistant to NA or ESC.
There was striking evidence of household clustering of
resistance, consistent with either spread of organisms
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sition, such as through shared contaminated food (8,12).
Most carriers of drug-resistant E. coli did not have expo-
sures previously associated with antimicrobial drug resist-
ance such as travel, contact with the healthcare system, or
chronic illness (13–15). 
NAresistance was associated with recent use of antimi-
crobial agents in the household. Use of antimicrobial
agents may have enhanced acquisition of exogenous NA-
resistant E. coli; alternatively, for persons who had recent-
ly taken fluoroquinolones, NA resistance may have
emerged during therapy. 
Overall, 36% of households had at least 1 member who
had received antimicrobial drug treatment within the pre-
vious 6 months, illustrating the magnitude of antimicrobial
drug selection pressure operating in a community. Self
reporting of antimicrobial drug use may be a useful mark-
er of exposure to these drugs when pharmacy records are
not available. However, the accuracy with respect to spe-
cific drugs was poor. 
This study did not convincingly support or refute the
hypothesis that contact with contaminated meat con-
tributes to gastrointestinal carriage of drug-resistant E.
coli. Only a small number of persons reported not eating
meat, and those persons lived in households where other
members ate meat. Therefore, persons not exposed to meat
were not adequately sampled.
The limitations of the study should be acknowledged.
Random recruitment of volunteers from the community
was not feasible. Since only a single stool specimen was
obtained, the duration of carriage of drug-resistant E. coli
or the timing of its onset in relation to specific exposures
could not be determined. The use of thymidine-containing
media (MacConkey agar) may have diminished the
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the screening for TMP/SMZ resistance. 
In conclusion, most home-living residents who carried
drug-resistant  E. coli lacked conventional risk factors.
Household-level antimicrobial drug use was associated
with carriage of NA-resistant but not TMP/SMZ-resistant
E. coli. The role of the food supply in promoting dissemi-
nation of drug-resistant E. coli in human populations war-
rants more detailed study. 
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